Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas

Catherine Gozé1, Marie Blonski1, Guillaume Le Maistre1

  • 1Cell Biology Laboratory, CHU Gui de Chauliac Hospital, Montpellier, France (C.G.); INSERM U1051 Institut des Neurosciences de Montpellier, Montpellier, France (C.G., H.D., L.B.); Centre des Collections Biologiques Hospitalières de Montpellier (CCBH-M), CHU Gui de Chauliac Hospital, Montpellier, France (C.G.); Réseau d'Etude des Gliomes, REG, Groland, France (C.G., M.B., L.B., L.C., L.T., J.P.); Department of Neuro-Oncology, Nancy Neurological Hospital, Nancy, France (M.B., H.D., J.D.); Department of Neurosurgery, Sainte-Anne Hospital, Paris, France (G.L.M., E.D., P.P., B.D., J.P.); University Paris Descartes, Paris, France (G.L.M., E.D., P.P., P.V., B.D., J.P.); Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier, France (L.B., H.D.); Department of Neuropathology, Sainte-Anne Hospital, Paris, France (P.V.); Department of Neurosurgery, Pitié-Salpêtrière University Hospital, Paris, France (L.C.); Department of Neuro-Oncology, CHU de Poitiers, Université de Poitiers, Poitiers, France (L.T.).

Neuro-Oncology
|May 22, 2014
PubMed
Abstract

Related Concept Videos